SCHEMBL6132393

SCHEMBL6132393

CCOC(=O)c1ccc(N2CCC(OCCCCCCOC)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.44
HPGD P15428 2/20 0.44
ALDH1A1 P00352 5/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.43
HSP90AA1 P07900 2/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
FDFT1 P37268 1/20 0.42
TSHR P16473 1/20 0.42
SIRT2 Q8IXJ6 2/20 0.41
SIRT1 Q96EB6 2/20 0.41
GAA P10253 1/20 0.41
BCHE P06276 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132246 1.00 HTT (0.44) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6134438 0.95 MEN1 (0.44) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6134511 0.91 ALDH1A1 (0.47) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6132432 0.91 ALDH1A1 (0.47) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6132359 0.91 ALDH1A1 (0.47) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6134525 0.90 HPGD (0.47) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6134902 0.90 ALDH1A1 (0.50) HTTHPGDALDH1A1KMT2APOLB
SCHEMBL7323856 0.87 ALDH1A1 (0.50) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6135042 0.85 FDFT1 (0.44) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL6132700 0.85 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MAPTTSHRBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 HTT 2637/4885HPGD 3020/4885ALDH1A1 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.